CHAPTER 42 — REFERENCES


88. Bunn PA Jr, Greco FA, Einhorn L. Cyclophosphamide, doxorubicin, and

75. Laberge F, Fritsche HA, Umsawasdi T, et al. Use of carcinoembryonic anti-

77. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography


68. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung: deri-

78. Chin R Jr, McCain TW, Miller AA, et al. Whole body FDG-PET for the

65. Dearing MP, Steinberg SM, Phelps R, et al. Outcome of patients with

63. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity im-

cancer is associated with decreased survival.

54. Tong W, Ma X, Zhang L, et al. The combination of etoposide and cis-

104. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment


106. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based che-

102. Nakanishi Y, Kusumi A, Hayashi N, et al. Comparison of etoposide-cispla-
in the combined modality treatment of limited-stage small-cell lung cancer.

73. Feigl B, Stohr J, Zehnacker J, et al. Randomized controlled trial of etoposide

76. Dehdashti F, Stitt LW, Quoix E, et al. Imaging and biologic markers in small-

59. Matsui T, Nakajima T, Nishi S, et al. Comparison of etoposide and cis-


64. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung: deri-

72. Pintiaux A, Hulot JS, Bontemps Y, et al. Irinotecan plus cisplatin as second-

92. Koeppen EB, Zaccarelli F, Manni L, et al. Randomized phase III trial of
cisplatin plus etoposide with or without thoracic irradiation in limited-stage
small-cell lung cancer—analysis of individual patient data.

90. Jackson DV Jr, Case LD, Zin EB, et al. Outcomes in patients with small-
cell lung cancer during 20 years of clinical research at the US National Cancer

81. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regi-
en is superior to etoposide and carboplatin for refractory or relapsed small-cell
lung cancer: results from a randomized phase III trial with 5 years’ follow-up.

cancer: posttreatment characteristics in patients surviving 5 to 18

and VP-16-213 in non-small-cell lung cancer patients treated with platinum-based chemotherapy.

survival in small-cell lung cancer: a new prognostic index and validation of

96. Messeih AA, Schweitzer JM, Lipton A, et al. Addition of etoposide to cy-
clophosphamide, doxorubicin, and vincristine for remission induction and
vincristine for remission induction and survival in patients with small-cell lung

containing regimen versus a regimen without this alkylating agent.

97. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin: an effective

94. Messeih AA, Schweitzer JM, Lipton A, et al. Addition of etoposide to cy-
clophosphamide, doxorubicin, and vincristine for remission induction and
vincristine for remission induction and survival in patients with small-cell lung

and carboplatin for refractory or relapsed small-cell lung cancer.


101. Maes M, Rademaker JW, van der Meulen FP, et al. Randomized phase III trial of
cisplatin plus etoposide chemotherapy with chest irradiation for small-cell lung cancer:
an individual patient data analysis of the EORTC 08941 trial. J Clin Oncol

cisplatin monotherapy in the second-line treatment of small-cell lung cancer
patients with previous chemotherapy: results of a phase III trial of the AIO.


obulin for the treatment of refractory or relapsed small-cell lung cancer.

106. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based che-

101. Maes M, Rademaker JW, van der Meulen FP, et al. Randomized phase III trial of
cisplatin plus etoposide chemotherapy with chest irradiation for small-cell lung cancer:
an individual patient data analysis of the EORTC 08941 trial. J Clin Oncol

cisplatin monotherapy in the second-line treatment of small-cell lung cancer
patients with previous chemotherapy: results of a phase III trial of the AIO.


obulin for the treatment of refractory or relapsed small-cell lung cancer.

106. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based che-

101. Maes M, Rademaker JW, van der Meulen FP, et al. Randomized phase III trial of
cisplatin plus etoposide chemotherapy with chest irradiation for small-cell lung cancer:
an individual patient data analysis of the EORTC 08941 trial. J Clin Oncol


233. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or...


235. Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax me-

236. Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navito-

237. Tan N, Malek M, Zha J, et al. Navitoclax enhances the efficacy of taxanes in pa-

238. Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of...

239. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavail-

240. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carbopla-


244. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family in-

245. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavail-

246. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carbopla-


249. Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax me-

250. Shoemaker AR, Albert I, Kovacs P, et al. A randomized phase II study of car-


252. Tan N, Malek M, Zha J, et al. Navitoclax enhances the efficacy of taxanes in pa-


254. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 in-

255. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 in-

256. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carbopla-

257. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 in-

258. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 in-

259. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 in-


261. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiotherapy and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its...


References


393. Travis WD, Krug LM, Rusch V, et al. Large Cell Neuroendocrine Carci-

394. Chapter 42 References R123


404. Travis WD, Krug LM, Rusch V, et al. Large Cell Neuroendocrine Carci-

405. Travis WD, Krug LM, Rusch V, et al. Large Cell Neuroendocrine Carci-


407. Travis WD. Neuroendocrine lung tumors. Path Case Reviews 2006;11:

408. Ross G, Cavazzza A, Marchioni A, et al. Role of chemotherapy and the recep-


